Back to News
Market Impact: 0.3
AbbVie's SKYRIZI Gets Health Canada Approval For Children With Moderate To Severe Plaque Psoriasis
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Health Canada approved AbbVie’s SKYRIZI (risankizumab) to treat children with moderate to severe plaque psoriasis. The article provides no sales, market-size, or share-price figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ABBV0.65
More News
- Morgan Stanley initiates ADARx stock with overweight rating
- Jio’s Record $3.2 Billion IPO Puts India’s Market Muscle to the Test
- A top medical technology stock is trading at a big discount. Here's why I'm buying
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people
- Why is Intuitive Surgical stock sliding today?